印度的醫藥品市場:2009∼2024年的展望 是由出版商Visiongain在2009年11月所出版的。
這份英文市場調查報告書包含160 pages 價格從美金2331起跳。
印度的醫藥品市場市全球擴大最迅速的市場之一。2009年的銷售額接近80億美金。2007年達25％最高峰、5年來的成長持續維持在兩位數。
本報告書內容包括:印度的醫藥品市場的現況和銷售預測、市場佔有率分析、開發中藥劑的動向等、同時利用圖表進行說明、內容綱要摘記如下: 封面圖片：  第1章 實施概要
第2章 印度的醫藥品市場
- 全球的市場：概要
- 印度市場：76億美金的機會
- 全球市場實績
- 全球市場的主要動向
- 印度醫藥品業界的動向
第3章 印度的醫藥品市場分析
- 急速擴大的市場
- 醫藥品市場分析
- 處方藥市場
- OTC醫藥品市場
- 非專利醫藥品市場
- 品牌藥品在2009∼2024年之間獲得很大的市場佔有率
- 高銷售的治療領域
- 治療藥品市場預測：抗感染藥品市場
- 治療藥品市場預測：抗感染藥品以外的市場
- 印度的治療藥品市場的急速成長領域
第4章 印度的醫藥品業界的主要參與企業
第5章 規範政策和架構
- 介紹
- 知識財產
- 規範的架構
- 醫藥品政策評估之Mashelkar Committee
- 2008∼2009年的預算
第6章 印度醫藥品市場的定性分析
- 概要
- 市場促進因子
- 市場阻礙因子
- 新興動向和機會
- 同業界所直接面臨的課題 其他
第7章 專家專訪
第8章 結論
圖表
Abstract
-can this rising pharma market sustain high growth from 2009 onwards? Our new
market study explains.
The Indian pharmaceutical market is one of the fastest growing in the world.
The rising Indian pharma market will achieve sales of close to $8 billion in
2009 and has enjoyed double-digit growth in the past five years, peaking at
25% in 2007. Will the Indian market continue to achieve high sales growth next
decade? Our new report - Indian Pharmaceutical Market Outlook 2009-2024 -
explains, providing the information that you need to understand this crucial
pharma opportunity. India is of rising importance as growth slows in the
current leading markets.
The strong growth registered by the Indian economy has helped to drive its
pharmaceutical market and industry. That sector' s growth in recent years has
also been driven by India' s expanding middle class, with growing affordability
and greater access to healthcare. India currently accounts for over 5% of the
Africa/Asia/Australasia market and is ranked 14th in the world pharmaceutical
markets. The highly-competitive market in India continues to be dominated by
Indian pharmaceutical companies, but remains fragmented, with over 20,000
licensed organisations. Besides many SMEs, competitors include
internationally-recognised companies such as Cipla, Dr. Reddy' s and Ranbaxy,
as well as foreign multinationals.
India' s pharmaceutical industry has strong potential for growth and will
continue to be an attractive sector for both domestic and foreign companies,
Indian Pharmaceutical Market Outlook 2009-2024 shows. Also, pharmaceutical
companies will continue to use acquisitions, joint ventures and leveraging of
low operational costs in India.
That country' s main strengths include:
- Second-largest population in the world, one predicted to overtake China' s
by 2035
- World' s second-fastest-growing economy
- Growing middle class with dispensable incomes and expanding healthcare
provision
- Highly-skilled workforce with competitive manufacturing base.
Therapeutic sales are not the only source of revenues for India' s
pharmaceutical sector. Increasing costs of research and manufacturing have
caused pharmaceutical companies worldwide to outsource operations to
lower-cost countries. India' s highly competitive pharma industry, with a
strong manufacturing base and relatively low overheads, offers strong
opportunities for outsourcing both research and production.
The growth of India' s pharmaceutical business is mostly driven by:
- Increases in production capacity and efficiency
- Legislative reforms
- The growth in contract manufacturing opportunities there
- Increases in outsourcing of clinical trials from higher-cost countries
- Research and development capabilities in both small-molecule and
biological drugs
- Foreign acquisitions and joint ventures by domestic companies.
Comprehensive analysis of the Indian pharmaceutical market and industry
Indian Pharmaceutical Market Outlook 2009-2024 examines that sector
critically, through a comprehensive review of information sources, both
primary and secondary. This report provides detailed sales forecasts, market
share analyses, discussions of pipeline developments and analyses of
commercial drivers and restraints, including a SWOT analysis. There are over
100 tables and figures included, as well as three full interviews with
relevant authorities. The result is a comprehensive market- and
industry-centred study, with detailed analyses and informed opinion to benefit
your work.
Research interviews from our comprehensive survey
This report contains visiongain interviews with the following relevant experts:
- 1) Dr Masaya Tamae, Director, Daiichi Sankyo, Tokyo, Japan
- 2) Dr Sanjeev Krishna, Professor of Molecular Parasitology & Medicine, St
George' s Hospital Medical School, London, UK
- 3) Dr Jagdish N Sheth, Professor of Marketing, Business School, Emory
University, USA.
Why you should buy Indian Pharmaceutical Market Outlook 2009-2024
In this report, you will receive the following benefits in particular:
- You will assess the value of the Indian pharma market and its principal
market segments from 2009 to 2024
- You will review the leading therapeutic areas in the Indian market,
including sales forecasts for 2009 to 2024, with detailed discussions
- You will obtain the latest developments in policy and regulations,
including guidelines on intellectual property and product patents
- You will examine commercial drivers and restraints, with comprehensive
SWOT analysis
- You will discover prominent domestic and foreign companies, with their
future prospects
- You will identify the most-promising emerging companies in the Indian
pharma market
Table of Contents
1. Executive Summary
- 1.1 Prospects for India' s Pharmaceutical Market
- 1.2 Aims, Scope and Format of the Report
- 1.3 Research Methods
2. The Indian Pharmaceutical Market
- 2.1 The Global Market: An Overview
- 2.2 Indian Market: $7.6bn Opportunity
- 2.3 Global Market Performances
- 2.3.1 US Market Expected to Contract in 2010.
- 2.3.2 Growth in EU and Japan will also Decelerate
- 2.3.3 Rapid Expansion in Emerging Markets
- 2.4 Key Trends in Global Market
- 2.4.1 M&A between Innovator & Generic Companies
- 2.4.2 Emerging Markets will Drive the Growth
- 2.4.3 The Future is an Increasingly Generic World
- 2.4.4 Greater Pressure on Cost & Price Reduction
- 2.5 The Trends in Indian Pharmaceutical Industry
3. Analysis of the Indian Pharmaceutical Market
- 3.1 A Rapidly Expanding Pharmaceutical Market
- 3.2 Pharmaceutical Market Analysis
- 3.3 Estimated Value for Prescription Market
- 3.4 Estimated Value for OTC Market
- 3.5 Estimated Market Volume for Generics
- 3.6 Branded Products Will Take Significant Market Share from 2009 to 2024
- 3.7 Major Selling Therapeutics Areas
- 3.7.1 Sales Figure for Major Therapeutics Areas
- 3.8 Forecasts for Major Therapeutics Market: Anti-Infective Medicines
- 3.8.1 Cephalosporins
- 3.8.2 Broad Spectrum Penicillins
- 3.8.3 Fluoroquinolones
- 3.8.4 Macrolides and Similar Types
- 3.9 Forecasts for Major Therapeutics Other than Anti-Infectives
- 3.9.1 Antiulcerants
- 3.9.2 Anti-rheumatics, Non-steroidal
- 3.9.3 Haematinics, Iron and All Combinations
- 3.9.4 Anti-epileptics
- 3.9.5 Antitussives
- 3.9.6 Multivitamins with Minerals
- 3.9.7 Biguanide Antidiabetics
- 3.10 Fastest Growing Classes in Indian Therapeutic Market
4. Key players in the Indian Pharmaceutical Industry
- 4.1 Introduction
- 4.2 The Chemical, Industrial & Pharmaceutical Laboratories (Cipla)
- 4.2.1 An Overview
- 4.2.2 Global Presence
- 4.2.3 Business Interests
- 4.2.4 Products
- 4.2.5 Revenue & Growth
- 4.3 Ranbaxy Laboratories
- 4.3.1 An Overview
- 4.3.2 Global Presence
- 4.3.3 Business Interests
- 4.3.4 Revenue & Growth
- 4.3.5 Therapeutic Focus Areas
- 4.3.6 Capabilities
- 4.3.7 Future Outlook
- 4.4 Piramal Healthcare
- 4.4.1 An Overview
- 4.4.2 Piramal' s Corporate Restructuring
- 4.4.3 Therapeutic Interests
- 4.4.4 Global Presence
- 4.4.5 Strengths & Capabilities
- 4.4.6 Revenues & Growth
- 4.5 Zydus Cadila
- 4.5.1 An Overview
- 4.5.2 Global Presence
- 4.5.3 Business Functions
- 4.5.4 Capabilities
- 4.5.5 R&D
- 4.5.6 Focus Therapeutic Segments
- 4.5.7 Revenue & Growth
- 4.5.8 Future Outlook
- 4.6 Dr. Reddy' s Laboratories
- 4.6.1 An Overview
- 4.6.2 Global Presence
- 4.6.3 Business Interests
- 4.6.4 Revenue & Growth
- 4.6.5 Capabilities
- 4.6.6 Future Outlook
- 4.7 Daiichi Sankyo
- 4.7.1 An Overview
- 4.7.2 Global Presence
- 4.7.3 Business Functions
- 4.7.4 Focus Therapeutic Segments
- 4.7.5 Revenue & Growth
- 4.7.6 Future Outlook
- 4.8 GlaxoSmithKline
- 4.8.1 An Overview
- 4.8.2 Therapeutic Areas
- 4.8.3 Revenue & Growth
- 4.8.4 Research & Development
- 4.8.5 Future Outlook
- 4.9 Abbott India Ltd
- 4.9.1 An Overview
- 4.9.2 Key Market Segments & Products
- 4.9.3 Revenues & Growth
- 4.10 Pfizer
- 4.10.1 An Overview
- 4.10.2 Products & Market Segment
- 4.10.3 Revenues & Growth
- 4.10.4 Pfizer' s Academic and Other Contributions
5. Regulatory Policy and Framework
- 5.1 Introduction
- 5.2 Intellectual Property: an Overview
- 5.2.1 A Brief Look at the Indian Patents Act, 1970.
- 5.2.2 India' s Membership of IPR Organisations
- 5.2.3 Compulsory Licenses and Foreign Technologies
- 5.2.4 Background to the WTO and TRIPS
- 5.2.5 Before TRIPS Lack of Patent Protection was Rife in Developing
Nations
- 5.2.6 Main Issues Addressed in IP Law
- 5.2.7 Summary of Key Points from the IPR
- 5.3 Regulatory Framework for the Pharma Industry
- 5.3.1 India' s Pricing Pattern for the Pharmaceutical Industry
- 5.3.2 National Pharmaceutical Pricing Authority (NPPA)
- 5.3.3 Drugs Price Control Order (DPCO), 1995
- 5.3.4 Understanding India' s Regulatory Environment
- 5.3.5 Central Government Responsibilities
- 5.3.6 State Government Responsibilities
- 5.3.7 A National Drug Authority (NDA) to be Formed
- 5.3.8 Central Drugs Standard Control Organisation (CDSCO)
- 5.3.9 The Drugs Controller General of India (DCGI)
- 5.3.10 Good Manufacturing Practice (GMP) Compliance
- 5.4 Mashelkar Committee on Reviewing Pharmaceutical Policy
- 5.5 2009: The National Pharmaceutical Policy is Under Review
- 5.6 Budget 2008-09: Perspective of the Pharma Industry
6. Qualitative Analysis of the Indian Pharmaceutical Market
- 6.1 An Overview
- 6.2 Drivers in the Indian market
- 6.2.1 India has a Large Untapped Market
- 6.2.2 Growing Middle Class is Driving Growth.
- 6.2.3 Large Base of Skilled Workforce
- 6.2.4 Cost-effective Manufacturing & Chemical Synthesis
- 6.2.5 Government Incentives and Tax Relief
- 6.3 Restraints in the Indian Market
- 6.3.1 Price Regulations
- 6.3.2 Low Penetrated Market
- 6.3.3 Fragmented Industry
- 6.4 Emerging Trends and Opportunities in the Indian Market
- 6.4.1 Product Development & Innovation
- 6.4.2 Drug Patent Expiries
- 6.4.3 Greater Penetration of Health Insurance
- 6.4.4 Outsourcing Hub for Contract Manufacturing
- 6.5 Challenges Facing Indian Pharmaceutical Industry
- 6.5.1 IP & Patents: Incremental Innovation has Become a Point of Concern
- 6.5.2 The Bolar Provision Concerns Foreign MNCs
- 6.5.3 Emerging Competition from China and Other Economies
- 6.6 Porter' s Five Forces Analysis of the Sector
- 6.6.1 Industry Competition
- 6.6.2 Bargaining Power of Buyers
- 6.6.3 Bargaining Power of Suppliers
- 6.6.4 Barriers to Entry
- 6.6.5 Threat of Substitutes
- 6.7 Objective Analysis.
- 6.7.1 Analysis: An Overview
- 6.7.2 Steps to Strengthen the Industry
- 6.8 Competition from Other Economies
- 6.9 Conclusion
7. Visiongain Interviews with Experts on the Indian Sector
- 7.1 Firsthand Interview for Expert Opinion 1
- 7.1.1 Challenges Facing Indian Industry
- 7.1.2 Will India be in the Top Five Largest Markets by 2020?
- 7.1.3 The Growing Problem of Counterfeit Drugs
- 7.1.4 The Pricing Structure and Prospects in the Future
- 7.1.5 The Growth in Sales of Patent and Generic Drugs by 2020
- 7.1.6 The Future Healthcare Coverage and Per Capita Spending
- 7.1.7 The Distribution System
- 7.1.8 Indian Government Support for Pharma & Biotech Industry
- 7.1.9 Potential of Indian Biotech Sector & Niche Areas
- 7.1.10 Networks in Indian Pharma & Biotech Industry
- 7.1.11 Manufacturing Competiveness
- 7.1.12 Treatments with Greatest Potential (2020) Relative to Price
Increases
- 7.1.13 Therapeutic Areas with Greatest Potential (2009-2020)
- 7.2 Firsthand Interview for Expert Opinion 2
- 7.2.1 Bureaucratic Challenges
- 7.2.2 Improving Access to Rural Areas
- 7.2.3 Therapeutic Areas Requiring Increased Attention (2009-2024)
- 7.2.4 Antibiotics, Drug Resistance and Unmet Needs
- 7.3 Firsthand Interview for Expert Opinion 3
- 7.3.1 India' s Key Strengths
- 7.3.2 India' s Edge over China in Pharmaceutical Business
- 7.3.3 Need for Routine Inspection of Outsourcing Sites
- 7.3.4 Need for Creation of Economic Zone for Pharmaceutical Industry
- 7.3.5 Business Approach Needed for Rural Mass
- 7.3.6 India as an Emerging Market
- 7.3.7 Growth of India' s Medical Tourism
- 7.3.8 Tropical Diseases Widespread in India
- 7.3.9 Vertical Integration Recommended for India' s Companies
- 7.3.10 India' s Emergence as a Major Pharmaceutical Market
8. Conclusions
- 8.1 Future Trends for Indian Pharma Industry
- 8.1.1 Greater Generic Penetration will Benefit Indian Producers
- 8.1.2 Biotechnology
- 8.1.3 Outsourcing and CRAMS
- 8.2 Looking to Developed Markets for Expansion
- 8.3 M&A are the Emerging Trend for Pharmaceutical Industry
- 8.4 Increasing Competition from China and Other Asian Countries
- 8.5 Measures to Increase Competitiveness of Indian Pharmaceutical Industry
- 8.5.1 Greater Investment into R&D
- 8.5.2 Academic-Industrial Partnership Model Should be Explored
- 8.5.3 India Should Exploit its Traditional Knowledge in Herbal Medicines
- 8.6 Future Outlook
List of Tables
- Table 2.1 Pharmaceutical Sales ($bn) of World Top 20 Nations, 2008
- Table 2.2 The Top 5 Nations with the Largest Populations in the World, 2009
- Table 2.3 Real GDP Growth Rates (%) for Leading Pharmaceutical Countries,
2006-2009
- Table 3.1 India' s Total Pharmaceutical Sales ($m), 2008-2014
- Table 3.2 India' s Total Pharmaceutical Sales ($m), 2015-2024
- Table 3.3 Long Range Forecasts for Indian Pharma Market, 2008, 2013, 2018
& 2024
- Table 3.4 CAGR (%) for Pharmaceutical Sales in India & the Total World
Market, 2008-2024
- Table 3.5 Prescription Market ($m), 2008-2015
- Table 3.6 Prescription Market ($m), 2016-2024
- Table 3.7 OTC & Prescription-Only Pharmaceutical Markets, 2008
- Table 3.8 Major OTC Categories in the Indian Market, 2008
- Table 3.9 Points of Sales for OTCs in the Indian Market, 2008
- Table 3.10 India' s International Market for OTC Drug Sales ($m), 2008-2014
- Table 3.11 India' s International Market for OTC Drug Sales ($m), 2015-2024
- Table 3.12 Indian National Market for OTC drugs, 2008-2015
- Table 3.13 Indian National Market for OTC drugs, 2016-2024
- Table 3.14 Major Drugs with Patent Expiry from 2009 to 2012
- Table 3.15 Type of Counterfeit Drugs on the Worldwide Market
- Table 3.16 Sales ($m) of Leading Anti-infectives in the Indian Market,
2007-08 & 2008-9
- Table 3.17 Sales ($m) of Leading Therapeutic Areas other than
Anti-infectives in the Indian Market, 2007-8 & 2008-9
- Table 3.18 Forecasts for Cephalosporins Sales ($m), 2008-2015
- Table 3.19 Forecasts for Cephalosporins Sales ($m) from 2016-2024
- Table 3.20 Forecasts for Broad Spectrum Penicillins Sales ($m) from
2008-2015
- Table 3.21 Sales Forecasts ($m) for Broad Spectrum Penicillins from
2016-2024
- Table 3.22 Forecasts for Fluoroquinolones Sales ($m) from 2008-2014
- Table 3.23 Forecasts for Fluoroquinolones Sales ($m) from 2016-2024
- Table 3.24 Forecasts for Macrolides and Similar Types ($m) from 2008-2015
- Table 3.25 Forecasts for Macrolides and Similar Types ($m) from 2016-2024
- Table 3.26 Forecasts for Antiulcerants ($m) from 2008-2015
- Table 3.27 Forecasts for Antiulcerants ($m) from 2016-2024
- Table 3.28 Forecasts for Anti-rheumatics, Non-steroidal from 2008-2015
- Table 3.29 Forecasts for Anti-rheumatics (Non-steroidal) from 2016-2024
- Table 3.30 Forecasts for Haematinics, Iron and all Combinations, 2008-2015
- Table 3.31 Forecasts for Haematinics, Iron and all Combinations, 2016-2024
- Table 3.32 Forecasts for Anti-epileptics from 2008-2015
- Table 3.33 Forecasts for Anti-epileptics from 2016-2024
- Table 3.34 Forecasts for Antitussives from 2008-2015
- Table 3.35 Forecasts for Antitussives from 2016-2024
- Table 3.36 Forecasts for Multivitamins with Minerals, 2008-2015
- Table 3.37 Forecasts for Multivitamins with Minerals, 2016-2024
- Table 3.38 Forecasts for Biguanide Antidiabetics, 2008-2015
- Table 3.39 Forecasts for Biguanide Antidiabetics, 2016-2024
- Table 3.40 Fastest Growing Therapy Classes in India, 12 Months to Q1
2009/2008
- Table 4.1 The Leading Corporate Groups in the Indian Pharmaceutical Market
- Table 4.2 The Leading Players in the Indian Market, 2009
- Table 4.3 Fastest Growing Local Companies from Top 50 in India
- Table 4.4 Cipla' s Worldwide Sales and Leading Markets, 2009
- Table 4.5 Sales of Cipla' s Leading Products by Therapeutic Class, 12
Months to Q1 2009
- Table 4.6 Selected List of New Drugs Launched by Cipla Worldwide in
2008-2009
- Table 4.7 Cipla' s Global Product Registration 2008-09
- Table 4.8 Piramal Healthcare - Top Selling Products, 12 Months to Q1 2009
- Table 4.9 Zydus Cadila' s Sales by Therapeutic Class in the Indian Market
- Table 4.10 Zydus Cadila' s Sale Figures for Leading Countries, 2009
- Table 4.11 Zydus Cadila - Sales by Region, 12 Months to Q1 2009
- Table 4.12 Zydus Cadila - Pipeline Products by Phase, 2009
- Table 4.13 Dr. Reddy' s Revenues from the Top 10 Brands in India, 2008-09
- Table 4.14 Daiichi Sankyo - Top Selling Products, 12 Months to Q1 2009
- Table 4.15 Daiichi Sankyo Product Pipeline by Phase, 2009
- Table 4.16 GlaxoSmithKline - Top Selling Products, 2009
- Table 4.17 Pfizer - Top Selling Products, 2009
- Table 5.1 Indian Membership of International IPR Organisations
- Table 6.1 SWOT Analysis for India' s Pharmaceutical Sector: Strengths
- Table 6.2 SWOT Analysis for India' s Pharmaceutical Sector: Weaknesses
- Table 6.3 SWOT Analysis for India' s Pharmaceutical Sector: Opportunities
- Table 6.4 SWOT Analysis for India' s Pharmaceutical Sector: Threats
Lists of Figures
- Figure 2.1 Worldwide Pharmaceutical Market, 2008
- Figure 2.2 World Market Share for Top 20 Pharmaceutical Nations, 2007
- Figure 2.3 Average Growth by Real GDP: ' Chindia' has the Highest Growth,
2006-2009
- Figure 3.1 India' s Total Pharmaceutical Sales ($m), 2008-2014
- Figure 3.2 India' s Total Pharmaceutical Sales ($m), 2015-2024
- Figure 3.3 CAGR (%) for Pharmaceutical Sales in India and the Total World
Market, 2008-2023.
- Figure 3.4 Indian Domestic and International Market Share, 2006
- Figure 3.5 Prescription Market ($m), 2008-2015
- Figure 3.6 Prescription Market ($m), 2016-2024
- Figure 3.7 Global Sales for OTC and Prescription-Only Pharmaceuticals, 2008
- Figure 3.8 Major Categories for Sales of OTCs in the Indian Market, 2008
- Figure 3.9 Points of Sales for OTCs in the Indian Market, 2008
- Figure 3.10 India' s International Market for OTC Drug Sales ($m) 2008-2024
- Figure 3.11 Indian National Market for OTC Drugs, 2008-2024
- Figure 3.12 Indian Share of the Global Generic Market by Volume, 2008
- Figure 3.13 Forecast for India' s Share of the Global Generic Market by
Volume in 2024
- Figure 3.14 Ratio of Patent and Generic Market Share in India by Value,
2008
- Figure 3.15 Visiongain Forecast for Ratio of Patent and Generic Market
Share in India by Value, 2024
- Figure 3.16 Sales ($m) for the Leading Anti-infectives in the Indian
Market, 2007-8 & 2008-9
- Figure 3.17 Leading Therapeutic Areas Other than Anti-infectives in the
Indian Market, 2007-8 & 2008-9
- Figure 3.18 Cephalosporins Sales ($m) Forecast for 2008-2014
- Figure 3.19 Cephalosporins Sales ($m) Forecast for 2015-2024
- Figure 3.20 Forecasts for Broad Spectrum Penicillins 2008-2015
- Figure 3.21 Forecasts for Broad Spectrum Penicillins 2016-2024
- Figure 3.22 Forecasts for Fluoroquinolones 2008-2015
- Figure 3.23 Forecasts for Fluoroquinolones 2016-2024
- Figure 3.24 Forecasts for Macrolides and Similar Types, 2008-2015
- Figure 3.25 Forecasts for Macrolides and Similar Types 2016-2024
- Figure 3.26 Forecasts for Antiulcerants, 2008-2015
- Figure 3.27 Forecasts for Antiulcerants, 2016-2024
- Figure 3.28 Forecasts for Anti-rheumatics (Non-steroidal), 2008-2015
- Figure 3.29 Forecasts for Anti-rheumatics (Non-steroidal), 2016-2024
- Figure 3.30 Forecasts for Haematinics, Iron and all Combinations, 2008-2015
- Figure 3.31 Forecasts for Haematinics, Iron and all Combinations, 2016-2024
- Figure 3.32 Forecasts for Anti-epileptics 2008-2015
- Figure 3.33 Forecasts for Anti-epileptics 2016-2024
- Figure 3.34 Forecasts for Antitussives, 2008-2015
- Figure 3.35 Forecasts for Antitussives, 2016-2024
- Figure 3.36 Forecasts for Multivitamins with Minerals, 2008-2015
- Figure 3.37 Forecasts for Multivitamins with Minerals, 2016-2024
- Figure 3.38 Forecasts for Biguanide Antidiabetics, 2008-2015
- Figure 3.39 Forecasts for Biguanide Antidiabetics, 2016-2024
- Figure 3.40 Fastest Growing Therapy Classes in India; Fixed Rate Growth
$(%), 12 Months to Q1 2009/2008
- Figure 6.1 SWOT Analysis of the Indian Pharmaceutical Industry, 2009
- Figure 8.1 Visiongain Model for Growth in the Indian Pharmaceutical
Market, 2009-2024
|
